Joe Hirman

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Messoud Ashina, Joel R. Saper, Roger Cady et al. · Cephalalgia · 2020 · 375 citations · Full text

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

David W. Dodick, Peter J. Goadsby, Stephen D. Silberstein et al. · The Lancet Neurology · 2014 · 369 citations

Gene-related Peptide, Cluster Headache, Frequent Episodic Migraine +6

Efficacy and safety of eptinezumab in patients with chronic migraine

Richard B. Lipton, Peter J. Goadsby, Jeff Smith et al. · Neurology · 2020 · 368 citations · Full text

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Jean‐Louis Vincent, M Ramesh, David Ernest et al. · Critical Care Medicine · 2013 · 315 citations

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Adam L. Boxer, Anthony E. Lang, Murray Grossman et al. · The Lancet Neurology · 2014 · 282 citations · Full text

Placebo-controlled Phase 2/3, Progressive Supranuclear Palsy, Rehabilitation +3